DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial

OUTLINE: This is a dose-escalation study. INDUCTION: Patients receive DR-18 subcutaneously (SC) once weekly on approximately days 0, 7, 14, and 21. MAINTENANCE: After induction treatment, following a two-week pause (GROUP 1 - Treatment) or following discontinuation of prophylactic systemic immunosuppression post-transplant (GROUP 2 - Prophylaxis) patients without grade 3-4 acute GVHD, grade 2 acute GVHD requiring ongoing systemic immunosuppression, or moderate/severe chronic GVHD may receive DR-18 SC approximately for 4 additional weeks. Additionally, patients undergo blood and bone marrow sample collection throughout the study. After completion of study treatment, patients are followed weekly for 4 weeks, monthly through 6 months and at 12 months.